Plus   Neg

THC Global To Commence Commercial Manufacture Of Medicinal Cannabis

Australian medicinal cannabis company THC Global Group said it has received a license from the Australian Therapeutic Goods Administration or TGA to manufacture therapeutic goods at its Southport Facility.

The company noted that the license, more commonly known as a GMP Licence, completes all the licences required for the company to commence commercial manufacture of medicinal cannabis at the facility.

A GMP Licence is a mandatory requirement for the commercial manufacture of medicinal cannabis in Australia. It is also mutually recognized for supply of pharmaceutical goods in 29 countries across Europe, Asia and Canada.

The GMP Licence will enable THC Global to manufacture Active Pharmaceutical Ingredient or API extracts, formulation and packaging of medicines, on-site testing and analysis, and supply of medicinal cannabis for human trials in Australia and globally.

THC Global noted that its Southport Facility is the largest pharmaceutical bio-floral extraction facility in the Southern Hemisphere, and one of the world's largest pharmaceutical GMP-licensed facilities for the manufacture of medicinal cannabis.

Following the receipt of the GMP License, THC Global said it will now seek to complete negotiations for the export supply of cannabis medicines. The company will utilize Australian-grown cannabis and imported crude extract to accelerate its timeline for local manufacture.

The company has commenced production of medicines under the oversight of newly appointed Chief Operating Officer of THC Pharma, Angela Macquire.

On Monday, THC Global said it signed a product supply agreement with biopharmaceutical company MGC Pharmaceuticals Ltd.

Under the agreement, MGC Pharma will provide THC Global with an immediate supplementary source of medicinal cannabis products, which will be packaged and made available to patients under the Canndeo brand.

Initially, THC Global will launch three oral liquid formulations in partnership with MGC Pharma. The company expects these products to be available for patients in Australia and New Zealand in the first quarter of 2020.

The agreement also provides for MGC Pharma and THC Global to collaborate on the future supply of API extracts as well as other finished product, including from THC Global's Southport facility.

For comments and feedback contact: editorial@rttnews.com

Health News

Follow RTT